Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis
AIM： To investigate the cumulative development incidence and predictive factors for idiopathic pulmonary fibrosis in hepatitis C virus （HCV） positive patients. METHODS： We studied 6150 HCV infected patients who were between 40-70 years old （HCV-group）. Another 2050 patients with hepatitis B virus （H...
Gespeichert in:
| Veröffentlicht in: | World journal of gastroenterology : WJG 2008-10, Vol.14 (38), p.5880-5886 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5886 |
|---|---|
| container_issue | 38 |
| container_start_page | 5880 |
| container_title | World journal of gastroenterology : WJG |
| container_volume | 14 |
| creator | Arase, Yasuji Suzuki, Fumitaka Suzuki, Yoshiyuki Akuta, Norio Kobayashi, Masahiro Kawamura, Yusuke Yatsuji, Hiromi Sezaki, Hitomi Hosaka, Tetsuya Hirakawa, Miharu Saito, Satoshi Ikeda, Kenji Kumada, Hiromitsu |
| description | AIM： To investigate the cumulative development incidence and predictive factors for idiopathic pulmonary fibrosis in hepatitis C virus （HCV） positive patients. METHODS： We studied 6150 HCV infected patients who were between 40-70 years old （HCV-group）. Another 2050 patients with hepatitis B virus （HBV） were selected as control （HBV-group）. The mean observation period was 8.0 ± 5.9 years in HCV-group and 6.3 ± 5.5 years in HBV-group. The primary goal is the development of idiopathic pulmonary fibrosis （IPF） in both groups. The cumulative appearance rate of IPF and independent factors associated with the incidence rate of IPF were calculated using the Kaplan- Meier method and the Cox proportional hazard model. All of the studies were performed retrospectively by collecting and analyzing data from the patient records in our hospital. RESULTS： Fifteen patients in HCV-group developed IPF. On the other hand, none of the patients developed IPF in HBV-group. In HCV-group, the cumulative rates of IPF development were 0.3% at 10th year and 0.9% at 20th year. The IPF development rate in HCV-group was higher than that in HBV-group （P = 0.021）. The IPF development rate in patients with HCV or HBV was high with statistical significance in the following cases： （1） patients ≥ 55 years （P 〈 0.001）; （2） patients who had smoking index （package per day x year） of ≥20 （P = 0.002）; （3） patients with liver cirrhosis （P = 0.042）. CONCLUSION： Our results indicate that age, smoking and liver cirrhosis enhance the development of IPF in HCV positive patients. |
| doi_str_mv | 10.3748/wjg.14.5880 |
| format | Article |
| fullrecord | <record><control><sourceid>wanfang_jour_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2751899</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>28566459</cqvip_id><wanfj_id>wjg200838014</wanfj_id><sourcerecordid>wjg200838014</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-dded7ff0f63f4c17c6286bdac665a1570d21b8ecb7a96fc539a6f68596d04b043</originalsourceid><addsrcrecordid>eNpVkUtrGzEURkVpaJy0q-7LUEo3ZVy9H5tAMUkTCGSTrIVGD1vuWHJGMwn599Vg0yYrXdDhu4f7AfAZwSURVP583q6XiC6ZlPAdWGCMVIslhe_BAkEoWkWwOAVnpWwhxIQw_AGcIikZU1IuwOW135sxjrE0q-YpDlNpfNqYZH1pYrLR-To2OTTRxVzJTbTNfup3OZnhpQmxG3KJ5SM4CaYv_tPxPQcPV5f3q-v29u73zerXbWspYWPrnHciBBg4CdQiYTmWvHPGcs4MYgI6jDrpbSeM4sEyogwPXDLFHaQdpOQcXBxy91O38876NA6m1_sh7qqOzibqtz8pbvQ6P2ksGJJK1YBvh4Bnk4JJa73N05Cqsq5XxBBKIiGa93w_7hny4-TLqHexWN_3Jvk8Fc0V51zgGfxxAG29Qxl8-OeCoJ7bmXM1onpup9JfXuv_Z491VODrMW6T0_oxVsHO2D8h9l5jyTinTJG_JQWYAA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69666724</pqid></control><display><type>article</type><title>Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis</title><source>MEDLINE</source><source>Baishideng "World Journal of" online journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Arase, Yasuji ; Suzuki, Fumitaka ; Suzuki, Yoshiyuki ; Akuta, Norio ; Kobayashi, Masahiro ; Kawamura, Yusuke ; Yatsuji, Hiromi ; Sezaki, Hitomi ; Hosaka, Tetsuya ; Hirakawa, Miharu ; Saito, Satoshi ; Ikeda, Kenji ; Kumada, Hiromitsu</creator><creatorcontrib>Arase, Yasuji ; Suzuki, Fumitaka ; Suzuki, Yoshiyuki ; Akuta, Norio ; Kobayashi, Masahiro ; Kawamura, Yusuke ; Yatsuji, Hiromi ; Sezaki, Hitomi ; Hosaka, Tetsuya ; Hirakawa, Miharu ; Saito, Satoshi ; Ikeda, Kenji ; Kumada, Hiromitsu</creatorcontrib><description>AIM： To investigate the cumulative development incidence and predictive factors for idiopathic pulmonary fibrosis in hepatitis C virus （HCV） positive patients. METHODS： We studied 6150 HCV infected patients who were between 40-70 years old （HCV-group）. Another 2050 patients with hepatitis B virus （HBV） were selected as control （HBV-group）. The mean observation period was 8.0 ± 5.9 years in HCV-group and 6.3 ± 5.5 years in HBV-group. The primary goal is the development of idiopathic pulmonary fibrosis （IPF） in both groups. The cumulative appearance rate of IPF and independent factors associated with the incidence rate of IPF were calculated using the Kaplan- Meier method and the Cox proportional hazard model. All of the studies were performed retrospectively by collecting and analyzing data from the patient records in our hospital. RESULTS： Fifteen patients in HCV-group developed IPF. On the other hand, none of the patients developed IPF in HBV-group. In HCV-group, the cumulative rates of IPF development were 0.3% at 10th year and 0.9% at 20th year. The IPF development rate in HCV-group was higher than that in HBV-group （P = 0.021）. The IPF development rate in patients with HCV or HBV was high with statistical significance in the following cases： （1） patients ≥ 55 years （P 〈 0.001）; （2） patients who had smoking index （package per day x year） of ≥20 （P = 0.002）; （3） patients with liver cirrhosis （P = 0.042）. CONCLUSION： Our results indicate that age, smoking and liver cirrhosis enhance the development of IPF in HCV positive patients.</description><identifier>ISSN: 1007-9327</identifier><identifier>EISSN: 2219-2840</identifier><identifier>DOI: 10.3748/wjg.14.5880</identifier><identifier>PMID: 18855988</identifier><language>eng</language><publisher>United States: ChinaDepartment of Hepatology, Toranomon Hospital, Tokyo 105-8470, Japan</publisher><subject>Adult ; Age Factors ; Aged ; Cause of Death ; Female ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - mortality ; Humans ; Idiopathic Pulmonary Fibrosis - mortality ; Idiopathic Pulmonary Fibrosis - virology ; Incidence ; Kaplan-Meier Estimate ; Liver Cirrhosis - virology ; Male ; Middle Aged ; Proportional Hazards Models ; Rapid Communication ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Smoking - adverse effects ; Time Factors ; 丙肝病毒 ; 乙肝病毒 ; 先天性肺纤维化</subject><ispartof>World journal of gastroenterology : WJG, 2008-10, Vol.14 (38), p.5880-5886</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><rights>2008 The WJG Press and Baishideng. All rights reserved. 2008</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-dded7ff0f63f4c17c6286bdac665a1570d21b8ecb7a96fc539a6f68596d04b043</citedby><cites>FETCH-LOGICAL-c435t-dded7ff0f63f4c17c6286bdac665a1570d21b8ecb7a96fc539a6f68596d04b043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/84123X/84123X.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2751899/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2751899/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18855988$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arase, Yasuji</creatorcontrib><creatorcontrib>Suzuki, Fumitaka</creatorcontrib><creatorcontrib>Suzuki, Yoshiyuki</creatorcontrib><creatorcontrib>Akuta, Norio</creatorcontrib><creatorcontrib>Kobayashi, Masahiro</creatorcontrib><creatorcontrib>Kawamura, Yusuke</creatorcontrib><creatorcontrib>Yatsuji, Hiromi</creatorcontrib><creatorcontrib>Sezaki, Hitomi</creatorcontrib><creatorcontrib>Hosaka, Tetsuya</creatorcontrib><creatorcontrib>Hirakawa, Miharu</creatorcontrib><creatorcontrib>Saito, Satoshi</creatorcontrib><creatorcontrib>Ikeda, Kenji</creatorcontrib><creatorcontrib>Kumada, Hiromitsu</creatorcontrib><title>Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis</title><title>World journal of gastroenterology : WJG</title><addtitle>World Journal of Gastroenterology</addtitle><description>AIM： To investigate the cumulative development incidence and predictive factors for idiopathic pulmonary fibrosis in hepatitis C virus （HCV） positive patients. METHODS： We studied 6150 HCV infected patients who were between 40-70 years old （HCV-group）. Another 2050 patients with hepatitis B virus （HBV） were selected as control （HBV-group）. The mean observation period was 8.0 ± 5.9 years in HCV-group and 6.3 ± 5.5 years in HBV-group. The primary goal is the development of idiopathic pulmonary fibrosis （IPF） in both groups. The cumulative appearance rate of IPF and independent factors associated with the incidence rate of IPF were calculated using the Kaplan- Meier method and the Cox proportional hazard model. All of the studies were performed retrospectively by collecting and analyzing data from the patient records in our hospital. RESULTS： Fifteen patients in HCV-group developed IPF. On the other hand, none of the patients developed IPF in HBV-group. In HCV-group, the cumulative rates of IPF development were 0.3% at 10th year and 0.9% at 20th year. The IPF development rate in HCV-group was higher than that in HBV-group （P = 0.021）. The IPF development rate in patients with HCV or HBV was high with statistical significance in the following cases： （1） patients ≥ 55 years （P 〈 0.001）; （2） patients who had smoking index （package per day x year） of ≥20 （P = 0.002）; （3） patients with liver cirrhosis （P = 0.042）. CONCLUSION： Our results indicate that age, smoking and liver cirrhosis enhance the development of IPF in HCV positive patients.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Cause of Death</subject><subject>Female</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - mortality</subject><subject>Humans</subject><subject>Idiopathic Pulmonary Fibrosis - mortality</subject><subject>Idiopathic Pulmonary Fibrosis - virology</subject><subject>Incidence</subject><subject>Kaplan-Meier Estimate</subject><subject>Liver Cirrhosis - virology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Proportional Hazards Models</subject><subject>Rapid Communication</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Smoking - adverse effects</subject><subject>Time Factors</subject><subject>丙肝病毒</subject><subject>乙肝病毒</subject><subject>先天性肺纤维化</subject><issn>1007-9327</issn><issn>2219-2840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUtrGzEURkVpaJy0q-7LUEo3ZVy9H5tAMUkTCGSTrIVGD1vuWHJGMwn599Vg0yYrXdDhu4f7AfAZwSURVP583q6XiC6ZlPAdWGCMVIslhe_BAkEoWkWwOAVnpWwhxIQw_AGcIikZU1IuwOW135sxjrE0q-YpDlNpfNqYZH1pYrLR-To2OTTRxVzJTbTNfup3OZnhpQmxG3KJ5SM4CaYv_tPxPQcPV5f3q-v29u73zerXbWspYWPrnHciBBg4CdQiYTmWvHPGcs4MYgI6jDrpbSeM4sEyogwPXDLFHaQdpOQcXBxy91O38876NA6m1_sh7qqOzibqtz8pbvQ6P2ksGJJK1YBvh4Bnk4JJa73N05Cqsq5XxBBKIiGa93w_7hny4-TLqHexWN_3Jvk8Fc0V51zgGfxxAG29Qxl8-OeCoJ7bmXM1onpup9JfXuv_Z491VODrMW6T0_oxVsHO2D8h9l5jyTinTJG_JQWYAA</recordid><startdate>20081014</startdate><enddate>20081014</enddate><creator>Arase, Yasuji</creator><creator>Suzuki, Fumitaka</creator><creator>Suzuki, Yoshiyuki</creator><creator>Akuta, Norio</creator><creator>Kobayashi, Masahiro</creator><creator>Kawamura, Yusuke</creator><creator>Yatsuji, Hiromi</creator><creator>Sezaki, Hitomi</creator><creator>Hosaka, Tetsuya</creator><creator>Hirakawa, Miharu</creator><creator>Saito, Satoshi</creator><creator>Ikeda, Kenji</creator><creator>Kumada, Hiromitsu</creator><general>ChinaDepartment of Hepatology, Toranomon Hospital, Tokyo 105-8470, Japan</general><general>The WJG Press and Baishideng</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope><scope>5PM</scope></search><sort><creationdate>20081014</creationdate><title>Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis</title><author>Arase, Yasuji ; Suzuki, Fumitaka ; Suzuki, Yoshiyuki ; Akuta, Norio ; Kobayashi, Masahiro ; Kawamura, Yusuke ; Yatsuji, Hiromi ; Sezaki, Hitomi ; Hosaka, Tetsuya ; Hirakawa, Miharu ; Saito, Satoshi ; Ikeda, Kenji ; Kumada, Hiromitsu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-dded7ff0f63f4c17c6286bdac665a1570d21b8ecb7a96fc539a6f68596d04b043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Cause of Death</topic><topic>Female</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - mortality</topic><topic>Humans</topic><topic>Idiopathic Pulmonary Fibrosis - mortality</topic><topic>Idiopathic Pulmonary Fibrosis - virology</topic><topic>Incidence</topic><topic>Kaplan-Meier Estimate</topic><topic>Liver Cirrhosis - virology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Proportional Hazards Models</topic><topic>Rapid Communication</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Smoking - adverse effects</topic><topic>Time Factors</topic><topic>丙肝病毒</topic><topic>乙肝病毒</topic><topic>先天性肺纤维化</topic><toplevel>online_resources</toplevel><creatorcontrib>Arase, Yasuji</creatorcontrib><creatorcontrib>Suzuki, Fumitaka</creatorcontrib><creatorcontrib>Suzuki, Yoshiyuki</creatorcontrib><creatorcontrib>Akuta, Norio</creatorcontrib><creatorcontrib>Kobayashi, Masahiro</creatorcontrib><creatorcontrib>Kawamura, Yusuke</creatorcontrib><creatorcontrib>Yatsuji, Hiromi</creatorcontrib><creatorcontrib>Sezaki, Hitomi</creatorcontrib><creatorcontrib>Hosaka, Tetsuya</creatorcontrib><creatorcontrib>Hirakawa, Miharu</creatorcontrib><creatorcontrib>Saito, Satoshi</creatorcontrib><creatorcontrib>Ikeda, Kenji</creatorcontrib><creatorcontrib>Kumada, Hiromitsu</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastroenterology : WJG</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arase, Yasuji</au><au>Suzuki, Fumitaka</au><au>Suzuki, Yoshiyuki</au><au>Akuta, Norio</au><au>Kobayashi, Masahiro</au><au>Kawamura, Yusuke</au><au>Yatsuji, Hiromi</au><au>Sezaki, Hitomi</au><au>Hosaka, Tetsuya</au><au>Hirakawa, Miharu</au><au>Saito, Satoshi</au><au>Ikeda, Kenji</au><au>Kumada, Hiromitsu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis</atitle><jtitle>World journal of gastroenterology : WJG</jtitle><addtitle>World Journal of Gastroenterology</addtitle><date>2008-10-14</date><risdate>2008</risdate><volume>14</volume><issue>38</issue><spage>5880</spage><epage>5886</epage><pages>5880-5886</pages><issn>1007-9327</issn><eissn>2219-2840</eissn><abstract>AIM： To investigate the cumulative development incidence and predictive factors for idiopathic pulmonary fibrosis in hepatitis C virus （HCV） positive patients. METHODS： We studied 6150 HCV infected patients who were between 40-70 years old （HCV-group）. Another 2050 patients with hepatitis B virus （HBV） were selected as control （HBV-group）. The mean observation period was 8.0 ± 5.9 years in HCV-group and 6.3 ± 5.5 years in HBV-group. The primary goal is the development of idiopathic pulmonary fibrosis （IPF） in both groups. The cumulative appearance rate of IPF and independent factors associated with the incidence rate of IPF were calculated using the Kaplan- Meier method and the Cox proportional hazard model. All of the studies were performed retrospectively by collecting and analyzing data from the patient records in our hospital. RESULTS： Fifteen patients in HCV-group developed IPF. On the other hand, none of the patients developed IPF in HBV-group. In HCV-group, the cumulative rates of IPF development were 0.3% at 10th year and 0.9% at 20th year. The IPF development rate in HCV-group was higher than that in HBV-group （P = 0.021）. The IPF development rate in patients with HCV or HBV was high with statistical significance in the following cases： （1） patients ≥ 55 years （P 〈 0.001）; （2） patients who had smoking index （package per day x year） of ≥20 （P = 0.002）; （3） patients with liver cirrhosis （P = 0.042）. CONCLUSION： Our results indicate that age, smoking and liver cirrhosis enhance the development of IPF in HCV positive patients.</abstract><cop>United States</cop><pub>ChinaDepartment of Hepatology, Toranomon Hospital, Tokyo 105-8470, Japan</pub><pmid>18855988</pmid><doi>10.3748/wjg.14.5880</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1007-9327 |
| ispartof | World journal of gastroenterology : WJG, 2008-10, Vol.14 (38), p.5880-5886 |
| issn | 1007-9327 2219-2840 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2751899 |
| source | MEDLINE; Baishideng "World Journal of" online journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adult Age Factors Aged Cause of Death Female Hepatitis C, Chronic - complications Hepatitis C, Chronic - mortality Humans Idiopathic Pulmonary Fibrosis - mortality Idiopathic Pulmonary Fibrosis - virology Incidence Kaplan-Meier Estimate Liver Cirrhosis - virology Male Middle Aged Proportional Hazards Models Rapid Communication Retrospective Studies Risk Assessment Risk Factors Smoking - adverse effects Time Factors 丙肝病毒 乙肝病毒 先天性肺纤维化 |
| title | Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T20%3A52%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatitis%20C%20virus%20enhances%20incidence%20of%20idiopathic%20pulmonary%20fibrosis&rft.jtitle=World%20journal%20of%20gastroenterology%20:%20WJG&rft.au=Arase,%20Yasuji&rft.date=2008-10-14&rft.volume=14&rft.issue=38&rft.spage=5880&rft.epage=5886&rft.pages=5880-5886&rft.issn=1007-9327&rft.eissn=2219-2840&rft_id=info:doi/10.3748/wjg.14.5880&rft_dat=%3Cwanfang_jour_pubme%3Ewjg200838014%3C/wanfang_jour_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69666724&rft_id=info:pmid/18855988&rft_cqvip_id=28566459&rft_wanfj_id=wjg200838014&rfr_iscdi=true |